News

Denali–Sanofi Partnership Dosing Alzheimer’s Patients in DNL747 Clinical Trial

Denali Therapeutics has begun dosing patients in its Phase 1b clinical trial of DNL747 as a treatment for Alzheimer’s disease. “We are excited to advance DNL747 in a second neurodegeneration indication based on Phase 1 healthy volunteer data regarding DNL747’s safety profile, CNS [central nervous system] penetration, and target engagement, at the studied doses,”…

Video Series Informs About the Possible Role of Germs in Alzheimer’s

Addressing fundamental questions about the possibility that Alzheimer’s disease might be brought about by infections, Alzheimer’s Germ Quest has released a series of eight videos, each about one minute long. Alzheimer’s Germ Quest supports research into the prospective infectious quality of the disease the Alzheimer’s Association says affects…